@mattpappas.bsky.social We estimated just one of the downstream harms of broad-spectrum antibiotics. But I hope this approach–trying to rigorously estimate harms for therapies that don’t have RCTs, rather than taking associations at face value–can help us be smarter about lots of treatments we use in the hospital. (8/9)